Biomarkers of cardiovascular disease: molecular basis and practical considerations
RS Vasan - Circulation, 2006 - Am Heart Assoc
echocardiogram) may be expected to facilitate the identification of patients with chest pain of
an ischemic etiology (angina). In a patient presenting to the emergency department with …
an ischemic etiology (angina). In a patient presenting to the emergency department with …
Potential role of activated platelets in homing of human endothelial progenitor cells to subendothelial matrix
EI Lev, Z Estrov, K Aboulfatova, D Harris… - Thrombosis and …, 2006 - thieme-connect.com
Endothelial progenitor cells (EPCs) mobilize from the bone marrow in response to tissue
injury and participate in vascular repair. However, there is limited data about the homing …
injury and participate in vascular repair. However, there is limited data about the homing …
Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of …
R Leo, G Di Lorenzo, M Tesauro, C Razzini… - Journal of Clinical …, 2006 - psychiatrist.com
Objective: Major depressive disorder (MDD) is associated with low-grade inflammation, and
it is considered a risk factor for coronary artery disease (CAD). CD40 ligand (CD40L) plays …
it is considered a risk factor for coronary artery disease (CAD). CD40 ligand (CD40L) plays …
Low-density lipoprotein-lowering medication and platelet function
Elevated low-density lipoprotein (LDL) cholesterol (LDL-C) levels represent one of the most
important risk factors for atherosclerosis and therefore cardiovascular morbidity and …
important risk factors for atherosclerosis and therefore cardiovascular morbidity and …
Soluble CD40L levels are regulated by the− 3459 A> G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST …
A Mälarstig, B Lindahl, L Wallentin… - … , and Vascular Biology, 2006 - Am Heart Assoc
Objectives—Current evidence suggests the CD40–CD40L pathway as a key process in the
development, progression, and outcome of acute coronary syndrome (ACS). The aim was to …
development, progression, and outcome of acute coronary syndrome (ACS). The aim was to …
Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque …
A Gómez-Hernández, E Sánchez-Galán… - Journal of …, 2006 - journals.lww.com
Abstract Prostaglandin E 2 (PGE 2), the product of cyclooxygenase-2 (COX-2) and
prostaglandin E synthase-1 (mPGES-1), acts through its receptors (EPs) and induces matrix …
prostaglandin E synthase-1 (mPGES-1), acts through its receptors (EPs) and induces matrix …
[HTML][HTML] Enhanced soluble CD40L in patients with the metabolic syndrome: Relationship with in vivo thrombin generation
Aims/hypothesis The metabolic syndrome is associated with proinflammatory and
prothrombotic states. This study was designed to assess the behaviour of soluble CD40 …
prothrombotic states. This study was designed to assess the behaviour of soluble CD40 …
Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease—a randomized …
HF Alber, M Frick, A Suessenbacher, J Doerler… - American heart …, 2006 - Elsevier
BACKGROUND: Coronary atherosclerosis includes an activation of circulating T
lymphocytes. Statins exert anti-inflammatory effects beyond lipid lowering. Whether these …
lymphocytes. Statins exert anti-inflammatory effects beyond lipid lowering. Whether these …
The effects of HMG-CoA reductase inhibitors on endothelial function
B Tesfamariam - American Journal of Cardiovascular Drugs, 2006 - Springer
Vascular endothelial dysfunction is a complex phenomenon that is caused by an imbalance
of vasodilator and vasoconstrictor factors that regulate the equilibrium-maintaining vascular …
of vasodilator and vasoconstrictor factors that regulate the equilibrium-maintaining vascular …
[HTML][HTML] Supplementation with mixed tocopherols increases serum and blood cell γ-tocopherol but does not alter biomarkers of platelet activation in subjects with type …
Background: Some studies have shown potential benefit of vitamin E on platelet function, but
several clinical trials failed to show improved cardiovascular outcome with α-tocopherol …
several clinical trials failed to show improved cardiovascular outcome with α-tocopherol …